Novartis: multiple sclerosis drug superior in two studies
(CercleFinance.com) - Novartis said that its ofatumumab drug was found to be more effective than a rival medicine from Sanofi in reducing the number of relapses in patients with multiple sclerosis.
In two Phase III studies, ofatumumab met primary endpoints to reduce the annualised relapse rate over Aubagio in patients with relapsing forms of the disease.
Ofatumumab, a potent, fully-human antibody targeting B-cells, also delivered a favourable safety profile, the company said.
Novartis plans to begin making submissions to health authorities by the end of 2019.
The Swiss drugmaker believes ofatumumab could be a highly attractive treatment option for a broad patient population, including those in early stages of multiple sclerosis.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In two Phase III studies, ofatumumab met primary endpoints to reduce the annualised relapse rate over Aubagio in patients with relapsing forms of the disease.
Ofatumumab, a potent, fully-human antibody targeting B-cells, also delivered a favourable safety profile, the company said.
Novartis plans to begin making submissions to health authorities by the end of 2019.
The Swiss drugmaker believes ofatumumab could be a highly attractive treatment option for a broad patient population, including those in early stages of multiple sclerosis.
Copyright (c) 2019 CercleFinance.com. All rights reserved.